The global obesity drug market, valued at approximately $95 billion, faces significant challenges due to the gastrointestinal side effects associated with popular weight-loss medications. Drugs such as Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound h…
Global Obesity Drug Market Valued at $95 Billion Faces Challenges from Gastrointestinal Side Effects
